Inhibrx, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: La Jolla CA United States (2010)

Organization Overview

First Clinical Trial
2018
NCT03715933
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Inhibrx, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

alpha-1 antitrypsin (Prolastin) (1 trial)

inbrx-101/rhaat-fc (3 trials)

inbrx-109 (2 trials)

Drugs in Phase 1 Trials (3)

inbrx-105 (1 trial)

inbrx-106 (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

alpha 1-Antitrypsin Deficiency (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Head and Neck Neoplasms (Phase 1)

Hodgkin Disease (Phase 1)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Melanoma (Phase 1)

Mesothelioma (Phase 1)

Sarcoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6